Harvest BMAC™ - New Stem Cell Treatment for Critical Limb Ischemia (CLI)

Harvest Technologies Corp.’s Harvest BMAC™ treatment for Critical Limb Ischemia has been found to reduce amputation rates significantly. Nearly all the patients who underwent this treatment had severe pain at rest and were already scheduled for leg amputation. All surgical and endovascular options had been previously exhausted. After the injection of a concentrate of the patients’ own bone marrow stem cells, leg amputation could be avoided in more than half of these patients. Under normal circumstances, the amputation rate in CLI is 90-100% in the patient population that was treated.

Injected autologous adult stem cell concentrates from bone marrow have been shown in international clinical studies to be significantly effective in achieving tissue regeneration in vascular, orthopedic and cardiac disease.

Until now, it has been difficult to process and concentrate a clinically significant dose of adult stem cells from a patient’s bone marrow. The BMAC System from Harvest Technologies is the world’s first and only technique that produces clinically significant amounts of adult stem and precursor cells from a small aspirate of autologous bone marrow in just 15 minutes.